Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.82 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.81 |
| ▸ | NPY1R | P25929 | 1/20 | 0.81 |
| ▸ | NPY2R | P49146 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoprolol SCHEMBL123230 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Metoprolol SCHEMBL10634188 | 0.96 | ADRB2 (0.75) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| (S)-Metoprolol SCHEMBL3123844 | 0.92 | ADRB2 (0.88) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Metoprolol SCHEMBL3123840 | 0.92 | ADRB2 (0.88) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| (S)-Metoprolol SCHEMBL9636561 | 0.92 | TDP1 (0.72) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Metoprolol SCHEMBL7274530 | 0.92 | TDP1 (0.72) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| (S)-Metoprolol SCHEMBL7274540 | 0.92 | TDP1 (0.72) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Metoprolol SCHEMBL9636584 | 0.92 | TDP1 (0.72) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Metoprolol SCHEMBL1561123 | 0.91 | ADRB1 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Metoprolol SCHEMBL4093 | 0.91 | ADRB1 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 711 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106309399-B | A kind of micro-pill type sustained release tablets and preparation method thereof | 深圳翰宇药业股份有限公司 | 2019-07-26 | — | — | CN | claimed |
| US-20180280405-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2018-10-04 | — | — | US | claimed |
| CN-103211792-B | Metoprolol fumarate film-controlled slow-release micro pill capsule | 北京天衡药物研究院有限公司 | 2018-02-02 | — | — | CN | claimed |
| WO-2017134200-A1 | A NOVEL PHARMACEUTICAL COMPOSITION OF VORAPAXAR AND METOPROLOL | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2017-08-10 | — | — | WO | claimed |
| WO-2017134199-A1 | A PHARMACEUTICAL COMPOSITION OF VORAPAXAR AND METOPROLOL | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2017-08-10 | — | — | WO | claimed |
| CN-105561323-A | Sustained-release pharmaceutical preparation for treating heart disease and preparation method thereof | BEIJING HOSPITAL OF MINI OF HEALTH | 2016-05-11 | — | — | CN | claimed |
| CN-105560186-A | Slow-release medicinal preparation for treating heart diseases | BEIJING HOSPITAL OF MINI OF HEALTH | 2016-05-11 | — | — | CN | claimed |
| CN-102784143-B | A kind of single layer osmotic pump regulated-release preparations containing metoprolol and felodipine | Institute of Toxicology and Drugs, Chinese Academy of Military Medical Sciences (CN) | 2015-09-30 | — | — | CN | claimed |
| CN-104523642-A | Metoprolol sustained-release tablet and preparation method thereof | TIAN WU | 2015-04-22 | — | — | CN | claimed |
| CN-102018658-B | Controlled release preparation and preparation method thereof | ZHONG SHUGUANG | 2014-03-12 | — | — | CN | claimed |
| WO-2001074394-A1 | NEW COMBINATION OF A BETABLOCKER AND A CHOLESTEROL-LOWERING AGENT | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| EP-0412053-B1 | Supercritical fluid and near critical gas extraction of organic solvents from formed articles | CIBA GEIGY AG (CH) | 1995-05-10 | — | — | EP | claimed |
| US-5287632-A | Supercritical fluid and near critical gas extraction of organic solvents from formed articles | CIBA-GEIGY CORPORATION (US) | 1994-02-22 | — | — | US | claimed |
| EP-0412053-A2 | Supercritical fluid and near critical gas extraction of organic solvents from formed articles | CIBA-GEIGY AG (CH) | 1991-02-06 | — | — | EP | claimed |
| US-4892739-A | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties | CIBA-GEIGY CORPORATION (US) | 1990-01-09 | — | — | US | claimed |
| EP-0148811-B1 | PHARMACEUTICAL COMPOSITION | LEJUS MEDICAL AKTIEBOLAG (SE) | 1989-09-06 | — | — | EP | claimed |
| US-4780318-A | DIFFERENT SOLUBILITIES AT DIFFERENT PHS | LEJUS MEDICAL AKTIEBOLAG (SE) | 1988-10-25 | — | — | US | claimed |
| EP-0148811-A1 | Pharmaceutical composition | LEJUS MEDICAL AKTIEBOLAG (SE) | 1985-07-17 | — | — | EP | claimed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280405-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ8 | ADRB1 446/4885ADRB2 664/4885ADRA1A 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.